US 12,433,859 patent landscape and claim-scope analysis for oral lisdexamfetamine dimesylate solution (buffer + non-aqueous cosolvent, pH 6.0-9.0, <1.0% total impurities after 4 weeks, antioxidant-free)

This US patent claim set is tightly focused on an oral liquid formulation of lisdexamfetamine dimesylate at 10 mg/mL with (i) a defined pH window, (ii) a defined solvent system (aqueous carrier + buffer + non-aqueous cosolvent selected from specified glycol/polyol classes), (iii) a stability/impurity limit after 4 weeks under accelerated conditions, and (iv) an antioxidant-free positioning (with explicit prohibited antioxidants in dependent claims). Scope is narrowest where all three elements are required together: exact API strength + cosolvent class and concentration bands + impurity limit + (optionally) antioxidant-free.

What does US 12,433,859 claim cover for lisdexamfetamine oral solution?

Core independent claim (Claim 1) requires all of:

Dosage form: oral pharmaceutical solution.
Strength: 10 mg/mL lisdexamfetamine dimesylate.
Liquid system: pharmaceutically acceptable aqueous carrier comprising a buffer and a non-aqueous cosolvent.
Cosolvent type: non-aqueous cosolvent “selected from a glycol, a polyol and a mixture thereof.”
pH: 6.0 to 9.0.
Stability/impurities: less than 1.0% total impurities after four weeks.

Strategic implication: Claim 1 is a “formulation definition” claim. It does not claim a specific manufacturing method, device, or kit. It will be asserted against products that match the formulation parameters and pass the impurity/stability criterion.

Why the stability limitation is a high-friction element

The “less than 1.0% total impurities after four weeks” ties the claim to quantitative product quality over time, which can be hard to “design around” without demonstrating comparable analytical outcomes under the same or substantially similar storage conditions.

Dependent claims 21 and 22 further specify the stress condition as 40°C / 75% RH for four weeks (Claim 21) and the same condition language (Claim 22) tied to the method context.
Practically, an accused product must show a test setup that leads to “total impurities” below the threshold. That makes the patent less vulnerable to superficial formulation swaps if a competitor keeps similar stability behavior.

Claim 1 does not specify:

Which exact glycol/polyol individual members are used (that appears in dependent claims).
Buffer identity (explicit examples appear in dependent claims, but Claim 1 only requires “a buffer”).
Presence/absence of preservatives (that is in dependent claim 10).
Antioxidant status (antioxidant-free is addressed in dependent claims 2-3).

What are the antioxidant-free and “no specific antioxidant” claim limitations?

Dependent claims create a clear anti-oxidant design boundary.

Claims 2–3: “free of any antioxidant” and “free of specific antioxidants”

Claim 2: solution is free of any antioxidant.
Claim 3: solution is free of antioxidants selected from:
- sodium metabisulfite
- butylated hydroxy anisole (BHA)
- butylated hydroxy toluene (BHT)
- ethylenediamine tetraacetic acid (EDTA)
- ascorbic acid
- α-tocopherol
- propyl gallate

Scope effect: These dependent claims narrow the protected products to those that do not include any antioxidant, or do not include those specific antioxidant excipients. Many commercial oral liquids include preservatives and sometimes chelators/antioxidants depending on formulation strategy; these claims can be used to argue infringement even if the rest of the formulation matches, depending on how courts treat multi-ingredient definitions.

Important internal tension in the claim set (buffer vs prohibited antioxidant):

Claim 12 lists ascorbic acid as an example buffer.
Claim 3 prohibits ascorbic acid as an antioxidant. A formulation could still “use ascorbic acid” as a buffer if it is not used as an antioxidant; however, the claim text treats it as an antioxidant prohibition. Litigators typically argue label/functional role. The claim set as written still creates leverage: accused parties will face argument that ascorbic acid presence violates Claim 3 if used as buffer.

Claim 12: buffer selection includes acetic acid, citrates/phosphates, and also ascorbic acid

Claim 12 provides buffer examples including ascorbic acid. That means Claim 1’s buffer requirement could be satisfied with buffers that are also listed as “antioxidants” in Claim 3. That overlap increases factual disputes about function and composition.

How do the pH and cosolvent concentration bands shape enforceable coverage?

pH range progression (Claims 7–8)

Claim 1: pH 6.0 to 9.0
Claim 7: pH 6.0 to 8.5
Claim 8: pH 6.5 to 8.0

These are not merely dependent narrowing for reading convenience. They can structure an infringement theory by creating multiple “landing zones.” If an accused product is, for example, pH 8.7, Claim 1 might still be implicated, but Claim 7 and Claim 8 would likely not.

Cosolvent concentration bands (Claims 4–6 and mirrored 13–15)

Claim 1 requires a cosolvent of glycol/polyol class but does not lock concentration. Dependent claims do:

Claim 4: total cosolvent 5 to 300 mg/mL
Claim 5: total cosolvent 50 to 250 mg/mL
Claim 6: total cosolvent 100 to 200 mg/mL

The same ranges appear in Claims 13–15 under the pH-limited subset of Claim 7.

Scope effect: concentration ranges can be the easiest design-around. A competitor can keep the pH and cosolvent type but move the total amount outside bands to avoid dependent claim coverage (though Claim 1 still requires “non-aqueous cosolvent” generally, so the independent claim may still be asserted).

Cosolvent composition examples (Claim 11)

Claim 11 enumerates non-aqueous cosolvents:

maltitol, glycerol, mannitol, sorbitol, xylitol
propylene glycol
low molecular weight polyethylene glycol
mixture thereof

Claim 11 matters because it translates the broad “glycol/polyol” class in Claim 1 into specific excipient members. Competitors using a different class not captured by this enumeration would still potentially be caught by Claim 1 depending on whether they can be argued as “glycol” or “polyol,” but Claim 11 narrows explicit infringement.

What stability and impurity requirements are protected, and how tight is the test?

Claim 1 stability threshold

<1.0% total impurities after four weeks

Claim 21 explicit accelerated conditions

“less than 1.0% total impurities after four weeks at 40°C and 75% relative humidity”

Claim 22 repeats the same conditions in method context

The method claims mirror the stability criteria tied to administration.

Scope implication for challenges and design-arounds:

If a competitor chooses a different buffer/cosolvent system, the key question becomes whether its “total impurities” after 4 weeks under comparable conditions are still below 1.0%.
Because the claim uses “total impurities,” the exact impurity definition (USP unspecified vs method-defined) can be a litigation focal point. The claim text itself is a functional/analytical endpoint.

What formulation features expand coverage through preservatives and “second cosolvent” additions?

Second non-aqueous cosolvent (Claim 9)

Oral solution comprises a second non-aqueous cosolvent.

This captures formulations with mixed solvent systems. It reduces the ability of a competitor to argue they avoided the claim because they used only one cosolvent.

Antimicrobial preservative (Claim 10, Claim 16 under pH-6.0-8.5 subset)

Oral solution comprises an antimicrobial preservative.

This creates a coverage bucket for preserved liquids. If a competitor uses an antioxidant-free, preservative-free approach, they may avoid Claims 10/16 but still potentially trigger Claim 1.

How is the method-of-use claim written, and what does it change in litigation?

Claims 19–20: treatment of ADHD via administration

Claim 19: method of treating ADHD in need thereof, administering the oral solution of Claim 1.
Claim 20: subject is a child.

Legal/strategic effect: Method-of-use claims are triggered by use (administration), not by manufacturing alone. In practice, an accused product that infringes the formulation claims also tends to infringe a method claim if the product is marketed and used for ADHD, including pediatric patients, because doctors prescribe accordingly.

Method claims can also affect litigation strategy around:

off-label use carve-outs (depending on evidence),
labeling and marketing,
and whether direct infringement theories align with sales of an ADHD-labeled product.

What specific claim combinations are the strongest “infringement hooks”?

From a patent enforcement standpoint, strongest hooks are combinations that are likely to be present in a realistic commercial product:

Exact strength + pH + cosolvent system + impurity stability
- Claim 1
Plus antioxidant constraints
- Claim 2 (free of any antioxidant) and/or Claim 3 (free of specific antioxidants)
Plus concentration band
- Claim 5 or Claim 6 (middle bands are often used in formulation)
Plus explicit cosolvent exemplars
- Claim 11
Plus accelerated stability condition
- Claim 21

The dependent claims provide multiple alternative theories. Even if the strongest dependent claim fails (for example, because pH or cosolvent concentration falls outside the band), Claim 1 can remain a backstop.

How does US 12,433,859 likely map onto lisdexamfetamine dimesylate liquid products in the US market?

Practical mapping categories

Lisdexamfetamine dimesylate oral liquid competitors usually fall into one of these buckets:

Conventional buffered aqueous liquids with a glycol/polyol co-solvent (for solubility and stability)
Liquids with antioxidants/chelators for oxidative control
Liquids with and without preservatives, depending on container closure system and dosing scheme

US 12,433,859 targets the subset that matches:

10 mg/mL strength
pH in 6.0-9.0
glycol/polyol cosolvent
and stays below the impurity threshold after 4 weeks

If a competitor’s liquid uses a different active strength (not 10 mg/mL), Claim 1 may be avoided, but method claims could still be tested via dosage equivalence arguments. The claim as written is tied to 10 mg/mL, so strength differences are a key design path.

What about “Orange Book” exclusivity and FDA regulatory status for lisdexamfetamine dimesylate oral solutions?

The provided claim text does not include the NDA/BLA number, Orange Book listing, or linkage information for US 12,433,859. Without the Orange Book entry and the FDA listed reference product, it is not possible to map:

patent term-to-expiration schedule,
regulatory exclusivity periods (NCE/505(b)(2/ANDA data exclusivity),
or whether this specific patent is listed for the oral solution listed drug.

No further patent-to-regulatory linkage analysis can be produced from the claims alone.

How strong is the patent estate around these claims, based on claim breadth alone?

Based strictly on the provided claim set:

Areas of strength

Parameter convergence: independent claim requires strength (10 mg/mL), pH window, cosolvent class, and a quantified stability endpoint.
Dependent antiox design: explicit antioxidant prohibitions provide litigation-grade constraints.
Explicit cosolvent concentration ranges: multiple bands create alternate infringement “targets.”
Stability under accelerated conditions: Claim 21 narrows “total impurities after 4 weeks” to a specific stress profile.

Areas that reduce breadth (potential design-around levers)

Exact strength requirement: products with a different concentration can potentially avoid Claim 1.
Cosolvent class wording: although “glycol” and “polyol” are broad, formulations using different solubilizers not argued to be glycol/polyol may be less exposed.
Antioxidant-free limitation in dependent claims: if competitors include an antioxidant, they may still infringe Claim 1 (since Claim 1 does not require antioxidant-free), but they avoid Claims 2-3. That reduces the number of dependent claims an opponent can assert.

What generic entry risks exist under this claim scope?

A generic entrant faces two practical risk zones:

Formulation match risk (direct infringement on product parameters)
- If the generic is marketed as 10 mg/mL and uses the same pH/cosolvent system and impurity performance, it risks infringement of Claim 1 and dependent claims.
Stability data risk (impurity threshold)
- Even if excipients are similar, failure to reach “<1.0% total impurities after four weeks” at the relevant conditions can avoid the claim.

Because the independent claim includes a stability outcome, generic formulation and stability validation become central to infringement risk, not just qualitative composition.

Claim-by-claim scope map (quick reference)

Claim	What it adds/limits	Key enforceability lever
1	10 mg/mL lisdexamfetamine dimesylate; oral solution; aqueous carrier with buffer + glycol/polyol cosolvent; pH 6.0-9.0; <1.0% total impurities after 4 weeks	Independent “formulation + stability” lock
2	free of any antioxidant	narrows to antioxidant-free products
3	free of specific antioxidants (metabisulfite, BHA, BHT, EDTA, ascorbic acid, α-tocopherol, propyl gallate)	enumerated excipient prohibition
4	cosolvent 5-300 mg/mL	concentration band
5	cosolvent 50-250 mg/mL	concentration band
6	cosolvent 100-200 mg/mL	concentration band
7	pH 6.0-8.5	narrower pH window
8	pH 6.5-8.0	narrower pH window
9	includes a second cosolvent	mixed cosolvent coverage
10	includes antimicrobial preservative	preserved liquid coverage
11	cosolvent exemplars list (maltitol, glycerol, mannitol, sorbitol, xylitol, propylene glycol, low MW PEG, mixtures)	enumerated excipients
12	buffer exemplars list incl. ascorbic acid, acetic acid, citrates, acetates, phosphates, calcium phosphates	enumerated buffer exemplars
13-18	mirror dependent ranges/exemplars but under pH 6.0-8.5 (Claim 7)	adds multi-parameter landing zones
19	method of treating ADHD via administering Claim 1 solution	use-based hook tied to formulation
20	subject is a child	broadens practical enforcement via pediatric use
21	<1.0% total impurities after 4 weeks at 40°C/75% RH	accelerated stability definition
22	same stability criterion in method context	mirrors stability requirement

Key Takeaways

US 12,433,859 is a formulation-and-stability patent: infringement depends on matching 10 mg/mL strength, pH 6.0-9.0, the presence of a glycol/polyol cosolvent in an aqueous buffered system, and achieving <1.0% total impurities after 4 weeks.
Antioxidant boundaries are explicit in dependent claims (Claims 2-3), including enumerated prohibited antioxidants; these reduce exposure for products that include antioxidants, but do not eliminate Claim 1 risk because Claim 1 itself is not antioxidant-free.
Dependent concentration bands (5-300; 50-250; 100-200 mg/mL) and pH bands (6.0-8.5; 6.5-8.0) create multiple enforceable subspaces.
Stability under 40°C/75% RH for 4 weeks (Claims 21-22) is the technical choke point for design-arounds and a focal metric for any infringement or non-infringement testing.
Method-of-use coverage (Claims 19-20) is tied to administering the Claim 1 formulation for ADHD, including pediatric patients.

FAQs

Can a formulation with a different lisdexamfetamine concentration than 10 mg/mL infringe Claim 1?
Claim 1 requires “10 mg/mL” in the oral solution, so concentration deviation is a primary design-around lever.
Does Claim 1 require the solution to be antioxidant-free?
No. Antioxidant-free limitations are in dependent Claims 2-3; Claim 1 only requires the buffer + glycol/polyol cosolvent system, pH range, and impurity threshold.
What cosolvents are explicitly named in the patent claims?
Claim 11 lists maltitol, glycerol, mannitol, sorbitol, xylitol, propylene glycol, and low molecular weight polyethylene glycol, plus mixtures.
What is the exact impurity threshold and time window in the claims?
Less than 1.0% total impurities after four weeks; Claims 21-22 specify 40°C and 75% RH for that four-week period.
Does the patent protect only product manufacture or also product use?
It includes a method-of-use claim (Claims 19-20) requiring administration of the Claim 1 oral solution for treating ADHD in the subject, including children.

References (APA)

United States Patent 12,433,859. (Claims provided in the prompt).

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Azurity	ARYNTA	lisdexamfetamine dimesylate	SOLUTION;ORAL	219847-001	Jun 16, 2025		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial	Y			INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2020416052	⤷ Start Trial
Brazil	112022012986	⤷ Start Trial
Canada	3165248	⤷ Start Trial
Chile	2022001792	⤷ Start Trial
Colombia	2022010594	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 12,433,859

Which drugs does patent 12,433,859 protect, and when does it expire?

Summary for Patent: 12,433,859